Loading
A phase 3 trial of Osimertinib, Datopotamab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer. ClinicalTrials.gov record last updated 2026-08-26: recruiting. Enrollment is planned at 582 participants. Primary completion is estimated at 2028-03-21. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Osimertinib, Datopotamab Deruxtecan. Registered primary measures: To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Progression Free Survival (PFS) by BICR in all randomised participants..
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Osimertinib, AstraZeneca.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/